Explore Video

View comprehensive coverage of Breast Cancer from ESMO 2022

Treating relapsed or refractory multiple myeloma (RRMM) can be complex and typically involves a combination of therapies based on the patient's previous treatments, overall health, and specific disease characteristics.

Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.

CAR-T cell therapies are approved for treatment of Diffuse Large B Cell Lymphoma (DLBCL) , Follicular Lymphoma & Mantle Cell Lymphoma.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

Advanced prostate cancer is characterized by intricate biological changes, including genetic and epigenetic alterations, as well as shifts in cellular metabolism.

Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).

Biosimilars are biologic medicines that are highly similar to an FDA-approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency.

Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.